Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00309842 · OUTCOME

Percentage Chimerism on Day 100

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases · Source last updated 2020-09-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percentage of donor cells
Interval / dispersion
Standard Deviation
Time frame
Day 100

What was measured

Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.

Groups in this outcome

Unrelated UCBT for Blood Cancers

Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Unrelated UCBT for Blood Cancers212

Reported measurements

Source class 1
Values in percentage of donor cells · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Unrelated UCBT for Blood Cancers98.18.5Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        8.5
        value
        98.1
denoms
  1. counts
    1. group Id
      OG000
      value
      212
    units
    Participants
description
Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.
dispersion Type
Standard Deviation
groups
  1. description
    Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
    id
    OG000
    title
    Unrelated UCBT for Blood Cancers
param Type
MEAN
reporting Status
POSTED
time Frame
Day 100
title
Percentage Chimerism on Day 100
type
SECONDARY
unit Of Measure
percentage of donor cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice